Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

Joseph J. Busch, Jr., M.D. , a board-certified radiologist and Founder of the Busch Center in Alpharetta, GA, will give a presentation titled "Robotic Assisted MRI-Guided Transurethral Ultrasound ...

Please provide your email address to receive an email when new articles are posted on . Staging from prostate-specific membrane androgen PET/CT had a significant association with PFS. Whole pelvis ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

As cancer care becomes both more advanced and more specialized, options in rural areas have shrunk.

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3 trials and a planned regulatory filing while ...

Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic ...

JAMP Pharma Group is a Canadian organization headquartered in Boucherville, in the Greater Montreal area. Having experienced exceptional growth over the last 10 years, JAMP Pharma Group is active in ...

The FDA has approved Lifyorli (relacorilant) plus Abraxane for certain platinum‑resistant ovarian cancer patients, offering a ...